Doug Hampton

Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia

by

SHANGHAI, May 16, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today the completion of patient enrollment in a multi-center Phase 3 clinical trial of etrasimod in Asia for the treatment of moderate-severe active ulcerative colitis … Read more

La FDA aprobó un nuevo medicamento para tratar los sofocos moderados a graves causados por la menopausia

by

In English  SILVER SPRING, Md., 16 de mayo de 2023 /PRNewswire-HISPANIC PR WIRE/– La Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) aprobó Veozah (fezolinetant), un medicamento oral para el tratamiento de síntomas vasomotores moderados a graves, o sofocos, causados por la menopausia. Veozah es el primer antagonista del receptor … Read more

Fresh2 Reports Fiscal Year 2022 Annual Financial Results

by

NEW YORK, May 16, 2023 /PRNewswire/ — Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,”Fresh2,” the “Company” or “we”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale … Read more

Vial Welcomes New VP of Operations, Ankit Agarwal

by

SAN FRANCISCO, May 16, 2023 /PRNewswire/ — Vial, a global tech-driven CRO providing next-generation clinical trial management services, has added Ankit Agarwal to their team. Agarwal will be the company’s new VP of Operations. Agarwal joins the team with over 10 years of experience in strategy and operations. He has worked in both large multinational … Read more

Quest Diagnostics Declares Quarterly Cash Dividend

by

SECAUCUS, N.J., May 16, 2023 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share, payable on July 25, 2023 to shareholders of record of Quest Diagnostics common stock on July 11, 2023. About Quest DiagnosticsQuest Diagnostics empowers people to take action … Read more

Fresh2 Reports First Quarter of Fiscal Year 2023 Financial Results

by

NEW YORK, May 16, 2023 /PRNewswire/ — Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., “Fresh2,” the “Company” or “we”) (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale … Read more

Waters Corporation Completes Acquisition of Light Scattering Leader Wyatt Technology

by

MILFORD, Mass., May 16, 2023 /PRNewswire/ — Waters™ Corporation (NYSE:WAT) today announced it has completed its acquisition of Wyatt Technology, a pioneer and well-recognized leader in innovative light scattering and field-flow fractionation instruments, software, accessories, and services. Wyatt accelerates Waters’ ability to build a high-growth business in bioanalytical characterization for new modalities. Tweet this Waters … Read more

Growing Demand for Small Molecule Drugs Fuels the Sector

by

DUBLIN, May 16, 2023 /PRNewswire/ — The “Small Molecule API Global Market Report 2023” report has been added to  ResearchAndMarkets.com’s offering. This report provides strategists, marketers and senior management with the critical information they need to assess the market. The global small molecule API market is expected to grow from $180.67 billion in 2022 to … Read more

Increasing Prevalence of Blood Cancer Cases Drives Growth

by

DUBLIN, May 16, 2023 /PRNewswire/ — The “Blood Cancer Drugs Global Market Report 2023” report has been added to  ResearchAndMarkets.com’s offering This report provides strategists, marketers and senior management with the critical information they need to assess the market. The global blood cancer drugs market will grow from $61.05 billion in 2022 to $66.17 billion in … Read more

REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium’s First Rare Disease Clinical Portfolio

by

Research in MPS IVA led by REGENXBIO scientists moving into clinic Donation of NAV® Technology licenses will support development of gene therapies for rare diseases ROCKVILLE, Md., May 16, 2023 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced that preclinical research in Mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio syndrome, was selected for … Read more